

## SUBJECT INDEX TO VOLUME 1

<p>Abl kinase inhibitor ..... 347</p> <p style="padding-left: 20px;">BIRB 796 as ..... 350</p> <p style="padding-left: 20px;">cyclin dependent kinase inhibitors as ..... 351</p> <p style="padding-left: 20px;">dasatinib as ..... 348</p> <p style="padding-left: 20px;">hydrazine derivatives as ..... 352</p> <p style="padding-left: 20px;">INNO-406 as ..... 349</p> <p style="padding-left: 20px;">nilotinib as ..... 349</p> <p style="padding-left: 20px;">ON012380 as ..... 350</p> <p style="padding-left: 20px;">second generation of ..... 347</p> <p style="padding-left: 20px;">SGX compounds as ..... 350</p> <p style="padding-left: 20px;">VX-608 as ..... 350</p> <p>Acridine ligands ..... 193</p> <p style="padding-left: 20px;">inhibition of RecQ-catalyzed tetraplex unwinding by ..... 193</p> <p>Amino-bisphosphonates ..... 383</p> <p style="padding-left: 20px;">antiangiogenic reports by ..... 389</p> <p style="padding-left: 20px;">antitumoral activity of ..... 387</p> <p style="padding-left: 20px;">chemical structure of ..... 383</p> <p style="padding-left: 20px;">clinical indications of ..... 384</p> <p style="padding-left: 20px;">effect on cancer cell adhesion/invasion/ viability ..... 388</p> <p style="padding-left: 20px;">effect on cancer growth factor release ..... 387</p> <p style="padding-left: 20px;">effect on osteoclast/osteoblast activity ..... 383</p> <p style="padding-left: 20px;">ibandronate as ..... 385</p> <p style="padding-left: 20px;">in cancer angiogenesis ..... 383</p> <p style="padding-left: 20px;">in human clinical models ..... 392</p> <p style="padding-left: 20px;">in preclinical models <i>in vitro</i> ..... 390</p> <p style="padding-left: 20px;">in preclinical models <i>in vivo</i> ..... 392</p> <p style="padding-left: 20px;">last generation of ..... 383</p> <p style="padding-left: 20px;">mechanisms of ..... 385</p> <p style="padding-left: 20px;">mindronate as ..... 385</p> <p style="padding-left: 20px;">new generation of ..... 384</p> <p style="padding-left: 20px;">proapoptotic effect on cancer cells ..... 388</p> <p style="padding-left: 20px;">zoledronic acid as ..... 385</p> <p>Angiogenesis ..... 105,153,224,389</p> <p style="padding-left: 20px;">angiostatin for ..... 156</p> <p style="padding-left: 20px;">endogenous inhibitors of ..... 225</p> <p style="padding-left: 20px;">endostatin for ..... 157</p> <p style="padding-left: 20px;">in cancer ..... 389</p> <p style="padding-left: 20px;">indolinones for ..... 156</p> <p style="padding-left: 20px;">kringle 5 for ..... 156</p> <p style="padding-left: 20px;">patents for cancer therapy targeting ..... 153</p> <p style="padding-left: 20px;">role of vascular endothelial growth factor (VEGF) in ..... 155</p> <p style="padding-left: 20px;">targeted therapies for ..... 233</p> <p style="padding-left: 20px;">tumor based ..... 153</p> <p>Anticancer agent ..... 1</p> <p style="padding-left: 20px;">amine platinum complexes as ..... 6</p> <p style="padding-left: 20px;"><i>cis</i>-diaminedichloro-platinum(II) as ..... 3</p> <p style="padding-left: 20px;">cisplatin analogs with carrier groups as ..... 5</p> <p style="padding-left: 20px;">diamine platinum complexes as ..... 7</p> <p style="padding-left: 20px;">multinuclear platinum complexes as ..... 11</p> <p style="padding-left: 20px;">nonclassical platinum compounds as ..... 13</p> <p style="padding-left: 20px;">platinum complexes as ..... 1</p> <p style="padding-left: 20px;">platinum coordination compounds as ..... 1</p> <p style="padding-left: 20px;">platinum-based ..... 4</p>	<p>pt(IV) coordination complexes as ..... 15</p> <p><i>trans</i>-platinum complexes as ..... 9</p> <p>Anticancer platinum complexes ..... 285</p> <p style="padding-left: 20px;">activity against cisplatin resistant cells ..... 290</p> <p style="padding-left: 20px;">derivatives of ..... 291</p> <p style="padding-left: 20px;">developments in ..... 285</p> <p>Anticancer therapy ..... 209</p> <p style="padding-left: 20px;">by anti-EGF-R antibodies ..... 209</p> <p style="padding-left: 20px;">by EGF-R small inhibitors ..... 209</p> <p style="padding-left: 20px;">target-based approaches in ..... 213</p> <p>Antisense oligodeoxynucleotides ..... 317</p> <p style="padding-left: 20px;">in cancer ..... 317</p> <p>Apoptosis ..... 81,313,334</p> <p style="padding-left: 20px;">c-Myc in ..... 313</p> <p style="padding-left: 20px;">signaling pathways of ..... 81</p> <p>Bcl-2 family ..... 334</p> <p style="padding-left: 20px;">role of ..... 335</p> <p>Bcr-Abl/T3151 clone ..... 347</p> <p>Bioactive lipid mediators ..... 369</p> <p style="padding-left: 20px;">by arachidonic acid cascade ..... 369</p> <p style="padding-left: 20px;">by cyclooxygenase pathway ..... 369</p> <p style="padding-left: 20px;">by lipoxygenase pathway ..... 372</p> <p style="padding-left: 20px;">COX-2 as ..... 370</p> <p style="padding-left: 20px;">cyclopentenone PGs as ..... 372</p> <p style="padding-left: 20px;">lipoxins as ..... 374</p> <p style="padding-left: 20px;">5-LO as ..... 373</p> <p style="padding-left: 20px;">12-LO as ..... 373</p> <p style="padding-left: 20px;">15-LO as ..... 374</p> <p style="padding-left: 20px;">lysophospholipids as ..... 376</p> <p style="padding-left: 20px;">regulation of cell proliferation/apoptosis by ..... 369</p> <p>Bortezomib ..... 397</p> <p style="padding-left: 20px;">in treatment of cancer ..... 397</p> <p style="padding-left: 20px;">induction of pro-apoptotic pathways by ..... 398</p> <p style="padding-left: 20px;">inhibition of angiogenic phenotype by ..... 399</p> <p style="padding-left: 20px;">mechanism of action of ..... 398</p> <p style="padding-left: 20px;">NF- B inhibition by ..... 398</p> <p>Calcium channel blockers ..... 109</p> <p style="padding-left: 20px;">dihydropyridines as ..... 109</p> <p style="padding-left: 20px;">imidazole derivatives as ..... 110</p> <p style="padding-left: 20px;">VOCs as ..... 109</p> <p>Calcium signaling ..... 106</p> <p style="padding-left: 20px;">activation by mitogens/angiogenic factors ..... 111</p> <p style="padding-left: 20px;">generation of ..... 106</p> <p style="padding-left: 20px;">specificity of ..... 114</p> <p>Cancer ..... 94,201,255,286,305,333,397</p> <p style="padding-left: 20px;">anthracycline compounds for ..... 256</p> <p style="padding-left: 20px;">apoptosis in ..... 334</p> <p style="padding-left: 20px;">camptothecin (CPT) analogs for ..... 268</p> <p style="padding-left: 20px;">c-Myc in ..... 313</p> <p style="padding-left: 20px;">combination therapies for ..... 203</p>
---	---

downstream targets in .....	305	patented targeted treatments of .....	319
energy flow in .....	330	regulation of activity of .....	307
immunotherapy for .....	201	therapeutic targeting of .....	316,318
inhibition of MMPs for .....	94	transcriptional activity of .....	307
natural MMP inhibitors for .....	94	turnover of .....	307
NADH in .....	333	Colorectal cancer (CRC) .....	175
patents therapeutic agents for .....	255	CAP plus oxaliplatin (XELOX) in first-line	
pathogenesis of .....	305	treatment of .....	175
platinum-based strategies in .....	286	Combination therapy .....	129
platinum-containing complexes for .....	256	dithiocarbamates in .....	131
podophyllotoxins analogs for .....	267	metal complexes in .....	131
proteasome inhibitors in .....	397	Cyclin dependent kinases (CDKS) .....	357
radiotherapy/chemotherapy for .....	39,203,204	based inhibitors containing 2-aminopyridine/	
taxane analogs for .....	268	2-aminopyrimidine heterocycles .....	362
treatment of .....	305	based inhibitors containing pyrazole/imidazole	
VDAC1 in .....	333	heterocycles .....	361
Checkpoint 1 inhibitors .....	55	based inhibitors in clinical trials .....	359
chemical structures of .....	57	based inhibitors under investigation .....	360
<i>in vitro</i> effects of .....	65	indolin-2-one based .....	362
<i>in vivo</i> tumor model studies of .....	65	inhibition of .....	357
inhibitory potencies of .....	57	inhibitors of .....	362
Chemotherapy .....	201	regulation of .....	357
Chronic myeloid leukemia (CML) .....	347	role in apoptosis .....	358
Cisplatin .....	130	role in cell cycle progression .....	358
photoactivation of .....	130	Cytokines .....	204
Cladribine .....	23	as radiosensitizers .....	204
administration of .....	24	Cytotoxic nucleoside analogues .....	163
clinical activity of .....	28	developments in .....	164
clinical efficacy in hematological malignancies .....	23	efficacy of .....	163
complications by .....	27	Cytotoxicity .....	133
in acute myeloid leukemia .....	32	Drug sensitivity .....	132
in chronic lymphocytic leukemia .....	28	Endogenous angiogenesis inhibitor .....	223
in hairy cell leukemia .....	28	angiostatin as .....	225
in langerhans cell histiocytosis .....	32	as therapeutic agent .....	223
in low grade non-Hodgkin's lymphoma .....	32	endorepellin as .....	231
in systemic mastocytosis .....	34	endostatin as .....	228
in Waldenström macroglobulinemia .....	31	endostatin-like fragment from type XV	
interactions with anti-neoplastic agents .....	27	collagen as .....	231
intravenous administration of .....	25	fibronectin fragment as .....	231
mechanism of action of .....	23	inhibitors of .....	231
older/new formulations of .....	23	kininogen as .....	230
oral administration of .....	26	pigment epithelium-derived factor as .....	231
pharmacokinetics of .....	24	platelet factor-4 (PF-4) as .....	231
pharmacology of .....	23	prolactin fragment as .....	230
side effect of .....	27	thrombospondin as .....	229
subcutaneous route of .....	27	type IV collagen-derived fragments as .....	229
c-Myc .....	305	Endothelial cells .....	105
activated expression in human tumors .....	316	Epidermal growth factor receptor (EGF-R) .....	209
alternative approaches for targeting .....	317	drugs inhibiting .....	210
based antisense oligodeoxynucleotides .....	317	intracellular targets of .....	210
epigenetic context of .....	315	overcoming resistance to .....	214
in apoptosis .....	310		
in cell differentiation .....	310		
in cell growth/proliferation .....	308		
in coronary artery restenosis .....	317		
in gene therapy .....	316		
in model super-competitor .....	312		
in tumor regression .....	315		

Flavopiridol .....	361	selective targeting to .....	330
analogues of .....	361	sustained high level calcium ion flows into .....	334
G4 DNA .....	187	to detect tumors .....	327
role of helicases .....	187	Mitochondrial targeted anti-cancer drugs .....	327
Gene expression .....	131	patent documents of .....	327
Gene therapy .....	201	MPTP .....	335
Gliostatin .....	172	regulation of .....	335
Hexokinase .....	330	N4-pentylloxycarbonyl-5'-deoxy-5-fluorocytidine	
as integration points of energy metabolism .....	330	(CAP) .....	173
as regulator of mitochondria in cancer cells .....	331	chemoradiation for locally advanced rectal	
in cancer cells .....	331	cancer with .....	176
studies in brain/comparison to cancer cells .....	331	clinical trials with .....	177
Inhibitor of apoptosis proteins (IAPs) .....	81	in breast cancer .....	174
antagonists of .....	84	in clinical setting .....	174
effect of livin on .....	86	in gastric cancer .....	177
effect of Omi/Htr A2 on .....	84	in head/neck cancer .....	178
effect of survivin on .....	86	in ovarian cancer .....	178
effect of XAF1 on .....	86	in prostate cancer .....	178
for diagnosis/treatment of human diseases .....	81	in renal cancer .....	178
function of .....	82	metabolic pathway of .....	173
in cancer .....	83	plus irinotecan (XELIRI) as first-line	
Smac/DIABLO agonists of .....	84	treatment for metastatic CRC .....	176
structure of .....	82	toxicity of .....	173
Intracellular calcium .....	105	Neuroendocrine tumors .....	243
Iressa .....	217	indications for SRS in diagnostic of .....	244
and chemotherapy .....	218	detection of SS receptors expressed in .....	243
MAD protein family .....	310	positron emission tomography (PET) in .....	243
Matrix metalloproteinase family .....	91	Nucleoside analogues .....	164
in cancer progression .....	93	CP-4055/CP-4126 as .....	164
Matrix metalloproteinase inhibitors .....	91	CYC-682 as .....	165
natural bio-drugs as .....	91	ethynylcytidine as .....	165
Metastasis .....	69	in gene therapy .....	167
development of .....	69	MB-7133 as .....	164
genomic/epigenetic of .....	70	NEO-6002 as .....	166
inhibitors for .....	69	oral formulations for .....	166
Mitocans .....	227	OSI-3876 as .....	165
as glucose analog inhibiting hexokinase .....	335	pronucleotides as .....	166
ANT inhibitors as .....	337	Oral lactoferrin .....	130
based therapies targeting BCL-2 family .....	340	PARP-1 .....	40
vitamin E analogs as .....	338	activation of .....	42
Mitochondria .....	327	catabolism of .....	42
based cell death pathway .....	334	in apoptotic pathways .....	43
based targeting tumor detection .....	328	in cell death .....	43
in cancer cells .....	330	in necrotic cell death .....	43
in cancer cells to cell survival .....	327	structure of .....	40
		substrates of .....	43
		Perylene derivatives .....	191
		as class of tetraplex binding anti-cancer drugs ....	191
		Platelet-derived endothelial cell growth factor .....	171
		as target for capecitabine .....	171

<i>cis</i> -Platinum complex .....	129	in gastroenteropancreatic system tumors .....	247
cytotoxicity of .....	129	in medullary thyroid carcinoma .....	245
with anti-tumor activity in combination therapy .....	129	in pheochromocytoma .....	245
Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor .....	39	in pituitary adenomas .....	244
-AB as .....	46	in pituitary tumors .....	247
benzimidazoles as .....	47	in small cell lung cancer .....	245
chemical classes of .....	46	therapeutic applications of .....	239
dihydroisoquinolinones as .....	47	Stem cells .....	121
in cancer chemotherapy .....	39,44	in normal tissues .....	121
indoles as .....	47	Telomerase .....	189
isoindolinones as .....	48	Telomeres .....	188
isoquinolinones as .....	47	end-replication problem of .....	188
nicotinamide as .....	46	targeting through G-quadruplex binding compounds .....	190
phenanthridinones as .....	49	Tetraplex binding molecules .....	185
phthalazinones as .....	48	as anti-cancer agents .....	185
quinazolinones as .....	48	as promotor target for anti-cancer therapy .....	191
zinc-fingers PARP-1 inhibitors as .....	49	as telomere target for anti-cancer therapy .....	187
Quadruplex DNA .....	186	assays to measure binding by molecular ligands .....	193
structural information on .....	186	cellular protein factors in metabolism of .....	186
Radiosensitizers .....	205	effect on telomerase function .....	190
antibody-drug combinations as .....	205	Tetraplex binding porphyrin TMPYP4 .....	192
Radiotherapy .....	201	regulation of transcriptional activation by .....	192
effect on immune response .....	206	Tetraplex DNA .....	185
Roscovitine .....	361	characteristics of .....	185
analogues of .....	361	properties of .....	185
Signal transduction molecules .....	76	Thymidine phosphorylase .....	171
as specific targets for inhibition of tumor cell migration .....	76	angiogenic properties of .....	171
Somatostatin (SS) .....	237	as target for capecitabine .....	171
receptors for .....	238	expression profiles in non-malignant/ malignant tissue .....	173
Somatostatin analogs .....	237	regulation of expression of .....	172
as tools for neuroendocrine tumor therapy .....	245	targeting therapy with .....	179
diagnostic use of .....	241	up-regulation by chemotherapeutic agents .....	172
in carcinoid tumors .....	244	up-regulation by radiotherapy .....	172
in diagnosis/treatment of neuroendocrine glands tumors .....	237	Tumor cell migration .....	71
in ectopic Cushing syndrome .....	245	positive/negative regulation of .....	71
in endocrine pancreatic tumors .....	244	Tumor stem cell niches .....	121
in gastroenteropancreatic (GEP) tumors .....	244	for action of anticancer drugs .....	121
		hypothesis for cancer treatment .....	123
		implications of .....	123
		strategies for .....	124